71st SSO Annual Cancer Symposium

Pancreatic Cancer

Using Neoadjuvant Therapy to Reduce Early Recurrences, Increase Survival in Patients With Pancreatic Cancer

USE OF THE FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a 4.9-month improvement in overall survival compared to gemcitabine/ nab-paclitaxel (Abraxane)...

Skin Cancer

Surgery After Checkpoint Blockade for Selected Patients With Metastatic Melanoma

“In the era of improved systemic therapy, checkpoint blockade for metastatic melanoma and the ability to surgically resect all disease after treatment are associated with survival of 75%, better than ...

Norman Wolmark, MD, and Bernard Fisher, MD, Honored for Leadership of NSABP

NORMAN WOLMARK, MD, and Bernard Fisher, MD, received the Society of Surgical Oncology (SSO) Distinguished Service Award for their work leading the National Surgical Adjuvant Breast and Bowel Project ...

solid tumors

SSO 2018: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Frozen section evaluation of sentinel lymph nodes after neoadjuvant chemotherapy has a higher false-negative rate than in the primary surgical setting, particularly for small tumor deposits. However, ...

gastrointestinal cancer

SSO 2018: Improved Survival With Nodal Downstaging in Gastric Cancer if ypN0 Is Achieved

A team of researchers led by Naruihiko Ikoma, MD, MS, of The University of Texas MD Anderson Cancer Center in Houston, analyzed outcomes in 316 patients with gastric cancer to determine...

skin cancer

SSO 2018: Outcomes of Patients With Metastatic Melanoma Selected for Surgery After Immunotherapy

Immunotherapy has transformed the treatment of metastatic melanoma, with 3-year survival rates surpassing 50% for appropriate patients. However, many of these patients still require surgery, but ...